U.S. Stocks Switched Between Small Gains and Losses Print
By Josh Gee   
Friday, 07 November 2014 15:22

With the main benchmarks hovering near record levels in the wake of a solid jobs report, a key payrolls data showed the economy added 214,000 jobs in October, while the unemployment rate ticked down to 5.8% — a broadly positive reading. Although the headline number was below the consensus of 243,000, the upward revisions to the previous two months more than made up for it.

Thinly-traded small cap Hanger Inc. (NYSE:HGR) drops on average volume after management rescheduled yesterday's Q3 earnings call to next week. Shares had been clawing their way back from the plummet on August 8 after it lowered guidance after missing Q2 consensus views.

Nano cap Repros Therapeutics Inc. (NASDAQ:RPRX) is up in early trading on above average volume in response to the company's report on its meeting with the FDA regarding its planned NDA submission for Androxal (isomer of clomiphene citrate).The agency did identify any additional clinical trials that would needed for the NDA filing, but did state that additional safety studies would be required in the future (post approval - Phase 4). The company believes it has the information and data it needs for the filing and does not expect to meet with the FDA again prior to making the submission.

Osiris Therapeutics, Inc.(NASDAQ:OSIR) Q3 results: Revenues: $17.2M (+149.3%); COGS: $3.8M (+100.0%); R&D Expense: $1.2M (+33.3%); SG&A: $10.9M (+172.5%); Operating Income: $1.2M (+999.0%); Net Income: $0.6M (+135.3%); EPS: $0.02 (+140.0%); Quick Assets: $592M (-9.9%); CF Ops: ($14.5M) (-72.6%).

After growing 9% Y/Y in Q2, Allscripts' (NASDAQ:MDRX) bookings fell 5% Y/Y in Q3 to $223M. The company blames the drop on the fact 2013 bookings included "a significant agreement for expanded software, services and managed services with PIH Health." Excluding the deal, bookings were up 16%. Nonetheless, on the CC (transcript), CEO Paul M. Black admitted Allscripts "would have liked to have delivered a stronger [bookings] performance," and that pricing is an issue. "It's -- not that there's a cut to our pricing, it's just the size of the deals are starting smaller and then you grow onto them from there."

ISIS Pharmaceuticals, Inc.(NASDAQ:ISIS) Q3 results: Revenues: $44.1M (+86.9%); R&D Expense: $61.1M (+33.7%); G&A: $4.5M (+32.4%); Operating Loss: ($21.5M) (+15.7%); Net Loss: ($26.7M) (-8.5%); Loss Per Share: ($0.23) (-9.5%); Quick Assets: $592M (-9.9%).

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!